ClinicalTrials.gg
Not yet recruitingNCT07679126MANTRAUpdated Oct 23, 2026

The Systemic Nature of Severe Traumatic Brain Injury

An observational study in Severe Traumatic Brain Injury, sponsored by Corewell Health West. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Corewell Health West · Observational

How we know

Updated Oct 23, 2026First site in United StatesStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 909 studies in Brain Injuries, Traumatic with a site in United States — 212 open to participants now, 250 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.

Planned enrollment
198th of 257
40 · median 120
Started
2026
with 64 others
Observational
258 of 909
56 open now
Primary completion
2028-07
later than 186 of 249 live
Registered
890th of 909
by date

Among the 909 studies in Brain Injuries, Traumatic with a site in United States, this one is the 198th largest by planned enrollment of the 257 observational ones that give a count, is one of 65 that started in 2026, is one of 258 observational ones, reaches primary completion later than 186 of the 249 other live ones, and was the 890th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

212 of the 909 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:

207 more — sign in →

All 212 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Brain Injuries, Traumatic with a site in United States, or all of them as a file.
02

Study summary

Severe traumatic brain injury (sTBI) is a devastating condition with no targeted therapies available to prevent secondary injury. Previous studies have demonstrated that brain injury in adolescents initiates an acute and robust immune response characterized by disruption of the blood-brain barrier and the formation of autoantibodies.

Alterations in the gut-brain axis may contribute to increased immune activation and autoantibody formation following sTBI. The primary objective of this study is to better understand the immune mechanisms involved in the interaction between brain injury and changes in gut permeability through the gut-brain axis.

To investigate these mechanisms, the study will use a multi-platform metabolomics approach in combination with ribonucleic acid (RNA) sequencing, cell-free deoxyribonucleic acid (cfDNA) analysis, and blood chemistry. These analyses will be used to evaluate early immune activation and the mechanisms associated with secondary and tertiary brain injury and neurodegeneration in adults with sTBI.

Read the detailed description

Detailed Description

Severe traumatic brain injury (sTBI) is a devastating condition for which no targeted therapies currently exist. Current acute management strategies are largely focused on stabilizing cerebral physiology rather than addressing the molecular mechanisms responsible for injury progression.

The initial traumatic injury and subsequent secondary injury processes, including neuroinflammation, neurotoxicity, and disruption of the blood-brain barrier (BBB), may contribute to a robust autoimmune response. Pilot studies in adolescents have demonstrated activation of a strong immune response characterized by BBB disruption and autoantibody formation. This response may contribute to short- and long-term inflammatory sequelae, including exacerbation of the initial injury, progression to chronic neurodegenerative disease, increased disability, and mortality.

Alterations in the gut-brain axis may serve as a potential source of increased immunogenicity and subsequent autoantibody formation. The primary objective of this project is to define the immune mechanisms involved in the interaction between brain injury and alterations in gut permeability through the gut-brain axis.

Metabolomics comprehensively profiles and quantifies small-molecule metabolites produced by cells, tissues, and microorganisms, allowing for the evaluation of metabolic pathways and their roles in specific biological processes. Although several omics studies have characterized time-dependent changes in adults and experimental models, comparable studies using multi-omics approaches in sTBI remain limited. This represents an important gap in understanding the biological mechanisms involved in injury progression.

Lipids are essential to cellular function because of their roles in membrane composition, cellular signaling, and energy metabolism, particularly within the brain. Lipidomics, a subfield of metabolomics, identifies and quantifies lipids across cell types, organs, and organisms. Investigation of cellular lipid pathways and networks may provide important insight into the molecular mechanisms underlying traumatic brain injury (TBI). Emerging lipidomic studies suggest that circulating and central nervous system (CNS)-derived lipid signatures are associated with injury severity, BBB disruption, and long-term neurodegenerative risk. Therefore, lipidomics may provide important information for the comprehensive evaluation of sTBI pathogenesis.

The gut-brain axis is a bidirectional communication network between the gastrointestinal tract and CNS. It has been implicated in the pathophysiology of several neurodegenerative disorders and, more recently, in TBI. Following sTBI, rapid alterations may occur in gastrointestinal motility, epithelial barrier integrity, immune signaling, and microbial community structure. Collectively, these changes may result in gut dysbiosis and increased intestinal permeability, potentially due to diffuse mucosal barrier dysfunction.

Maintenance of gastrointestinal mucosal integrity requires coordinated interactions between the epithelial lining, associated cellular junctions, and immune mechanisms that regulate permeability and absorption. In contrast, the BBB is highly regulated and relatively impermeable under normal physiological conditions. Following brain injury, BBB permeability may increase, allowing the entry of molecules that would not typically cross the barrier. These peripheral disturbances may contribute to neuroinflammation, oxidative stress, and neurodegeneration. However, the precise mechanisms underlying these interactions remain unclear and are a primary focus of this study.

To identify the cells and molecular pathways involved in these alterations, single-cell RNA sequencing (scRNA-seq) will be combined with global metabolomics, with particular emphasis on identifying unique gut-derived metabolites, including bacterial products and food antigens that are not typically detected in serum. Single-cell RNA sequencing will be used to identify circulating cell types and clonal activation. These findings will be integrated with metabolomic data to further characterize the mechanisms through which increased gut permeability may contribute to neurotoxicity following sTBI.

This multi-omics approach is intended to develop a comprehensive model of the cellular and molecular mechanisms involved in the interaction between the gut and brain following sTBI. Ultimately, these findings may identify potential therapeutic targets aimed at reducing immune activation and attenuating secondary and tertiary brain injury.

03

Conditions studied

  • Severe Traumatic Brain Injury
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients diagnosed with sTBI as defined as a Glascow Coma Scale (GCS) of 8 or less

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients must be between the ages of 18 to 65 at time of enrollment
  • Study group cohort will consist of at least 20 patients admitted with severe TBI, defined as a GSC less than or equal to 8 with evidence of intracranial pathology on imaging.
  • Trauma control cohort will include at least 10 patients matched on demographics and injury patterns without traumatic brain injury.
  • Healthy control cohort will be comprised of 10 patients without acute traumatic injury or illness, matched to the sTBI patients based on demographics and medical comorbidities.

Exclusion criteria

Exclusion Criteria:

  • Pregnant Patients
  • Prisoners
  • Patients less than 18 years of age or greater than 65 years of age
  • Patients with a penetrating brain injury mechanism, known neurodegenerative or psychiatric disorders, prior known traumatic brain injury, intracranial neoplasm, patients receiving massing transfusion or blood products prior to arrival, terminal illness or not expected to survive, confirmed or suspected brain death, known or immunological condition, receiving or immunomodulatory therapies, having a cardiac event leading to the injury, or for whom consent is unable to be obtained.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Study Group

    The first cohort (Study Group) will consist of at least 20 patients admitted to CH Butterworth Hospital with a severe TBI, defined as a GCS ≤ 8 with evidence of intracranial pathology on imaging.

  • Trauma Control

    The second cohort (Trauma Control) will include at least 10 patients matched on demographics and injury patterns without traumatic brain injury (head AIS 0).

06

What researchers measure

Primary outcomes

  1. Systemic immune and metabolic responses after sTBI

    Characterize the circulating cellular transcriptome using Bulk RNA-seq and single-cell RNA sequencing ScRNA-seq, compared to trauma and healthy controls to identify circulating cell types, clonal activity, and antibody formation that contribute to injury progression.

    Time frame: Time of injury and 1-month

  2. Identifying the mechanisms of immune activation driving secondary injury

    Define barrier disruption by performing both the 1H NMR and LC-MS metabolomic analysis (global, targeted, and lipidomics), transcriptomics, and proteomics to measure gut and blood-brain barrier permeability and markers of inflammation and neurodegeneration. Pinpoint cell types, pathways, and antibody-mediated mechanisms contributing to progressive brain injury by integrating transcriptomic and metabolomic datasets.

    Time frame: 1 year

  3. Establishment of a biorepository for future biomarker discovery and data integration with the sTBI patient registry for long-term follow-up.

    Bank stool and oral flora samples to study gut dysbiosis and investigate the link between gut microbiome and TBI and longitudinal downstream metabolic consequences leading neurodegeneration and psychiatric pathologies· Bank bronchoalveolar lavage (when available), and plasma for additional future ScRNA analyses at defined timepoints. Establish longitudinal outcomes by leveraging a newly developed sTBI registry to follow patients over time, linking early immune and barrier changes with long-term risk of neurodegeneration.

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2028, 19 months later.

Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 19 months is below that.

Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 1, 2026
StartEst.
Dec 1, 2026was Jul 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in United States
Show site
  • Corewell Health West · Grand Rapids, United States
Oct 23, 2026
Start date
Jul 1, 2026→Dec 1, 2026
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site added — first site in United States
    Show site
    • Corewell Health West · Grand Rapids, United States
    Start date Jul 1, 2026→Dec 1, 2026
    + 3 other changes: verification date, responsible party and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07679126
Lead sponsor
Corewell Health West
Collaborators
Corewell Health East
Responsible party
Alistair Chapman (Principle Investigator, Corewell Health West) — Principal investigator
First posted
Jul 1, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Ashley Franklyn
Contact
Ashley.Franklyn@corewellhealth.org
6163914051
Elizabeth A Steensma, MD, FACS
principal investigator · Corewell Health West

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion